Evaluation of pain associated with oral mucositis during the acute period after administration of high‐dose chemotherapy
Authors:
- David CellaDCDavid Cella
- Stephen T. SonisSSStephen T. Sonis
Open Access
Abstract
BACKGROUND No single oral mucositis (OM) assessment scale is universally accepted; the most commonly used scales are deficient because they combine subjective and objective measures and do not capture the patient's perspective. Because pain is the hallmark symptom of OM, the authors sought to determine whether a simple measure of patient‐reported pain was correlated with objective, physician‐assessed measures of OM. The findings of the current study may provide a clinical context for understanding the relation between objective indicators and patients' perceptions of OM. METHODS Three hundred twenty‐three patients receiving stomatotoxic chemotherapy and randomized to receive either iseganan or placebo for treatment of OM underwent periodic objective and subjective evaluations of OM. Objective measures included clinician scoring of stomatitis and dysphagia using the National Cancer Institute Common Toxicity Criteria scales. A subjective measure was obtained by having patients complete a questionnaire (with questions based on an 11‐point numeric scale) regarding oral pain. RESULTS More than 90% of scheduled oral assessments were obtained. Mouth pain scores were closely related to stomatitis and dysphagia; peak mouth pain coincided with peak stomatitis and dysphagia. Analgesic use increased by 0.7 days for each unit rise on the pain scale. Patients receiving iseganan had a significantly lower level of peak mouth pain than did patients receiving placebo (P = 0.041). CONCLUSIONS A separate measurement of patient‐reported pain was useful for capturing the patient's perspective on OM and was correlated with the physician's objective assessment. These findings support the use of a simple, patient‐reported rating of mouth pain as a clinically relevant and responsive endpoint in clinical trials. This rating system also may provide a straightforward method of following OM in clinical practice. Cancer 2003;98:406–12. © 2003 American Cancer Society. DOI 10.1002/cncr.11505Keywords
This publication has 14 references indexed in Scilit:
- Iseganan HCl: a novel antimicrobial agentExpert Opinion on Investigational Drugs, 2002
- Defining Clinically Meaningful Outcomes in the Evaluation of New Treatments for Oral Mucositis: Oral Mucositis Patient Provider Advisory BoardCancer Investigation, 2002
- Oral Mucositis Complicating Chemotherapy and/or Radiotherapy: Options for Prevention and TreatmentCA: A Cancer Journal for Clinicians, 2001
- Mucositis associated with stem cell transplantation: current status and innovative approaches to managementBone Marrow Transplantation, 2001
- Oral Mucositis and the Clinical and Economic Outcomes of Hematopoietic Stem-Cell TransplantationJournal of Clinical Oncology, 2001
- Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescueBritish Journal of Haematology, 2000
- A brief pain diary for ambulatory patients with advanced cancerCancer, 2000
- Evaluation of the use of a pain diary in chronic cancer pain patients at homePain, 1999
- Regimen-related toxicity in patients undergoing bone marrow transplantation.Journal of Clinical Oncology, 1988
- Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseasesPain, 1983